The European application was withdrawn before a decision, and the reasoning that was published

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
Theratechnologies submitted a marketing authorisation application for tesamorelin to the European Medicines Agency and withdrew it in 2012 before the Committee for Medicinal Products for Human Use issued an opinion. The agency published, as it does for withdrawals, a summary of the committee position at the time: concerns that the visceral fat reduction had not been shown to translate into clinical benefit, that the effect reversed on stopping, and that the long-term safety consequences of raised IGF-1 and altered glucose were uncertain in a condition that was not life-threatening. The drug has since been approved in Canada and remains available in the United States. It has never been authorised in the European Union.

The European position

European assessors weighed a surrogate endpoint — centimetres of visceral fat on a scan — against the absence of any shown effect on cardiovascular events, quality of life beyond a questionnaire, or mortality, and against the need for indefinite treatment with its costs and uncertainties. For a disfiguring but not dangerous condition they judged the balance unproven. The company chose withdrawal over a negative opinion.

The published withdrawal letter and the agency summary are the public record.

The contrast with the United States

The United States regulator accepted visceral fat reduction as a meaningful endpoint in this population and approved with labelling that stated the uncertainties. The two decisions reflect different thresholds for surrogate endpoints rather than different data. Canada approved later on the same evidence. The divergence is a standard example in regulatory science of how the same trials can support different conclusions.

No outcome trial has since resolved the question either way.

Why it is here

Because the regulatory record is part of what is established about the molecule, and a reader should know that one major regulator declined to find the evidence sufficient. It describes regulatory history and no use of the pack.

Tesamorelin is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Tesamorelin Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

The European position?

European assessors weighed a surrogate endpoint — centimetres of visceral fat on a scan — against the absence of any shown effect on cardiovascular events, quality of life beyond a questionnaire, or mortality, and against the need for indefinite treatment with its costs and uncertainties. For a disfiguring but not dangerous condition they judged the balance unproven. The company chose withdrawal over a negative opinion.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Tesamorelin Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.